Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients

Rohit Sheshgiri; Finn Gustafsson; Jill Sheedy; Vivek Rao; Heather J Ross; Diego H Delgado

doi:10.1016/j.healun.2009.07.009

Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients

Rohit Sheshgiri, Finn Gustafsson, Jill Sheedy, Vivek Rao, Heather J Ross, Diego H Delgado

23 Citations (Scopus)

Abstract

BACKGROUND: Human leukocyte antigen-G (HLA-G), a protein primarily expressed during pregnancy, helps maintain maternal-fetal immune tolerance. Myocardial and/or soluble HLA-G (sHLA-G) expression confers protection against rejection and vasculopathy after heart transplantation. Although the precise mechanisms remain unclear, immunosuppressive therapy has been reported to influence this expression. METHODS: We compared sHLA-G expression in heart transplant recipients receiving two different anti-proliferative agents: mycophenolate mofetil (MMF) and everolimus (RAD). Twelve-hour pharmacokinetic (PK) studies were conducted in patients after cyclosporine (CsA) administration in conjunction with RAD or MMF, during which plasma HLA-G concentrations were measured by enzyme-linked immunoassay (ELISA). RESULTS: Among patients receiving RAD, 78% expressed detectable levels of plasma HLA-G (1,002 +/- 511 ng/ml) compared with 25% of patients receiving MMF (612 +/- 438 ng/ml, p = 0.03). In all sHLA-G(+) patients, expression remained constant, with no significant changes in HLA-G levels throughout the 12-hour PK study period. CsA did not appear to influence sHLA-G expression, as there was no correlation between HLA-G levels and CsA exposure (R(2) = 0.43, p = 0.08). CONCLUSIONS: These preliminary findings suggest a disproportionate expression of HLA-G in patients under two distinct immunosuppression strategies after heart transplantation. Although CsA administration does not influence sHLA-G levels, RAD but not MMF is associated with sHLA-G expression. Larger prospective clinical investigations are required to confirm whether RAD is independently associated with increased HLA-G expression.

Original language	English
Journal	Journal of Heart and Lung Transplantation
Volume	28
Issue number	11
Pages (from-to)	1193-7
Number of pages	4
ISSN	1053-2498
DOIs	https://doi.org/10.1016/j.healun.2009.07.009
Publication status	Published - 2009

Access to Document

10.1016/j.healun.2009.07.009

Cite this

@article{8759248067d711df928f000ea68e967b,

title = "Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients",

abstract = "BACKGROUND: Human leukocyte antigen-G (HLA-G), a protein primarily expressed during pregnancy, helps maintain maternal-fetal immune tolerance. Myocardial and/or soluble HLA-G (sHLA-G) expression confers protection against rejection and vasculopathy after heart transplantation. Although the precise mechanisms remain unclear, immunosuppressive therapy has been reported to influence this expression. METHODS: We compared sHLA-G expression in heart transplant recipients receiving two different anti-proliferative agents: mycophenolate mofetil (MMF) and everolimus (RAD). Twelve-hour pharmacokinetic (PK) studies were conducted in patients after cyclosporine (CsA) administration in conjunction with RAD or MMF, during which plasma HLA-G concentrations were measured by enzyme-linked immunoassay (ELISA). RESULTS: Among patients receiving RAD, 78% expressed detectable levels of plasma HLA-G (1,002 +/- 511 ng/ml) compared with 25% of patients receiving MMF (612 +/- 438 ng/ml, p = 0.03). In all sHLA-G(+) patients, expression remained constant, with no significant changes in HLA-G levels throughout the 12-hour PK study period. CsA did not appear to influence sHLA-G expression, as there was no correlation between HLA-G levels and CsA exposure (R(2) = 0.43, p = 0.08). CONCLUSIONS: These preliminary findings suggest a disproportionate expression of HLA-G in patients under two distinct immunosuppression strategies after heart transplantation. Although CsA administration does not influence sHLA-G levels, RAD but not MMF is associated with sHLA-G expression. Larger prospective clinical investigations are required to confirm whether RAD is independently associated with increased HLA-G expression.",

author = "Rohit Sheshgiri and Finn Gustafsson and Jill Sheedy and Vivek Rao and Ross, {Heather J} and Delgado, {Diego H}",

note = "Keywords: Adult; Aged; Area Under Curve; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; HLA Antigens; Heart Transplantation; Histocompatibility Antigens Class I; Humans; Immunosuppressive Agents; Male; Maternal-Fetal Exchange; Middle Aged; Mycophenolic Acid; Prednisone; Pregnancy; Pregnancy Proteins; Sirolimus",

year = "2009",

doi = "10.1016/j.healun.2009.07.009",

language = "English",

volume = "28",

pages = "1193--7",

journal = "Journal of Heart and Lung Transplantation",

issn = "1053-2498",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients

AU - Sheshgiri, Rohit

AU - Gustafsson, Finn

AU - Sheedy, Jill

AU - Rao, Vivek

AU - Ross, Heather J

AU - Delgado, Diego H

N1 - Keywords: Adult; Aged; Area Under Curve; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; HLA Antigens; Heart Transplantation; Histocompatibility Antigens Class I; Humans; Immunosuppressive Agents; Male; Maternal-Fetal Exchange; Middle Aged; Mycophenolic Acid; Prednisone; Pregnancy; Pregnancy Proteins; Sirolimus

PY - 2009

Y1 - 2009

N2 - BACKGROUND: Human leukocyte antigen-G (HLA-G), a protein primarily expressed during pregnancy, helps maintain maternal-fetal immune tolerance. Myocardial and/or soluble HLA-G (sHLA-G) expression confers protection against rejection and vasculopathy after heart transplantation. Although the precise mechanisms remain unclear, immunosuppressive therapy has been reported to influence this expression. METHODS: We compared sHLA-G expression in heart transplant recipients receiving two different anti-proliferative agents: mycophenolate mofetil (MMF) and everolimus (RAD). Twelve-hour pharmacokinetic (PK) studies were conducted in patients after cyclosporine (CsA) administration in conjunction with RAD or MMF, during which plasma HLA-G concentrations were measured by enzyme-linked immunoassay (ELISA). RESULTS: Among patients receiving RAD, 78% expressed detectable levels of plasma HLA-G (1,002 +/- 511 ng/ml) compared with 25% of patients receiving MMF (612 +/- 438 ng/ml, p = 0.03). In all sHLA-G(+) patients, expression remained constant, with no significant changes in HLA-G levels throughout the 12-hour PK study period. CsA did not appear to influence sHLA-G expression, as there was no correlation between HLA-G levels and CsA exposure (R(2) = 0.43, p = 0.08). CONCLUSIONS: These preliminary findings suggest a disproportionate expression of HLA-G in patients under two distinct immunosuppression strategies after heart transplantation. Although CsA administration does not influence sHLA-G levels, RAD but not MMF is associated with sHLA-G expression. Larger prospective clinical investigations are required to confirm whether RAD is independently associated with increased HLA-G expression.

AB - BACKGROUND: Human leukocyte antigen-G (HLA-G), a protein primarily expressed during pregnancy, helps maintain maternal-fetal immune tolerance. Myocardial and/or soluble HLA-G (sHLA-G) expression confers protection against rejection and vasculopathy after heart transplantation. Although the precise mechanisms remain unclear, immunosuppressive therapy has been reported to influence this expression. METHODS: We compared sHLA-G expression in heart transplant recipients receiving two different anti-proliferative agents: mycophenolate mofetil (MMF) and everolimus (RAD). Twelve-hour pharmacokinetic (PK) studies were conducted in patients after cyclosporine (CsA) administration in conjunction with RAD or MMF, during which plasma HLA-G concentrations were measured by enzyme-linked immunoassay (ELISA). RESULTS: Among patients receiving RAD, 78% expressed detectable levels of plasma HLA-G (1,002 +/- 511 ng/ml) compared with 25% of patients receiving MMF (612 +/- 438 ng/ml, p = 0.03). In all sHLA-G(+) patients, expression remained constant, with no significant changes in HLA-G levels throughout the 12-hour PK study period. CsA did not appear to influence sHLA-G expression, as there was no correlation between HLA-G levels and CsA exposure (R(2) = 0.43, p = 0.08). CONCLUSIONS: These preliminary findings suggest a disproportionate expression of HLA-G in patients under two distinct immunosuppression strategies after heart transplantation. Although CsA administration does not influence sHLA-G levels, RAD but not MMF is associated with sHLA-G expression. Larger prospective clinical investigations are required to confirm whether RAD is independently associated with increased HLA-G expression.

U2 - 10.1016/j.healun.2009.07.009

DO - 10.1016/j.healun.2009.07.009

M3 - Journal article

C2 - 19783164

SN - 1053-2498

VL - 28

SP - 1193

EP - 1197

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

IS - 11

ER -

Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients

Abstract

Access to Document

Fingerprint

Cite this